Class I VAD Units Recalls Continue From Abbott, Medtronic
HeartMate and Medtronic’s HeartWare ventricular assist device platforms have been tagged with class I recalls in the last few weeks based on separate safety issues.
You may also be interested in...
2018 Earnings Spotlight: Transcatheter Valve Repair Remains Big Drivers For Medtronic, Edwards, Abbott
Reported sales and earnings from the publicly traded cardiovascular device companies in 2018 were generally strong, led by transcatheter aortic valve replacement devices, but some sectors of the industry, especially ventricular assist devices and peripheral drug-coated balloons, face significant challenges. Here's a recap of results from the cardio device companies that have reported so far, with a focus on Medtronic, Edwards, and Abbott.
With recent actions, the Medtronic HeartWare left-ventricular assist device system, acquired last year, has 11 class I recall actions to its name in the US.
HeartWare has found a way to pay for the expanded commercialization of its HVAD ventricular assist device and the development of its MVAD miniaturized ventricular assist device; the Boston-area VAD-maker has agreed be acquired by medtech giant Medtronic for $1.1bn in cash.